AABB Endorses Bill to Protect Access to Laboratory-Developed Tests
February 26, 2025
AABB joined a coalition of health care organizations to
endorse the Freedom for Laboratory Innovation and Testing Act, which seeks to prevent implementation of the Food and Drug Administration’s
final rule regulating laboratory-developed tests (LDTs). The bill, introduced by Reps. Brad Finstad (R-Minn.) and Dan Crenshaw (R-Texas), would preserve patient access to these diagnostic tools by blocking federal funding for enforcement of the FDA’s final rule.
AABB believes that LDTs play a critical role in patient care, particularly for individuals with rare diseases and complex conditions, where LDTs often serve as the only or most reliable diagnostic option. AABB is concerned that FDA’s rule would impose unnecessary regulatory burdens, potentially delaying access to testing and hindering innovation in diagnostic development.
Additional information for AABB member facilities preparing to implement FDA’s LDT final rule is available on the
AABB website.
